Partner Sarah Brooks will be moderating a panel, titled "Did the Supreme Court get it right?: A discussion of the implications of Helsinn v. Teva on the biotech/pharma industry." The panel will discuss practical tips for reducing the likelihood that an invalidating prior art sale is created between parties. In Helsinn v. Teva, the Supreme Court affirmed the invalidation of Helsinn's patent because of a confidential license and purchase agreement made between Helsinn and a third party more than one year prior to the filing of the patent and during the development phase of nausea drug Aloxi. The panel includes Venable counsel Ben Pelletier; U.S. District Court Judge Marilyn Huff; Sanjesh Sharma, Senior Counsel, Intellectual Property, Johnson & Johnson Surgical Vision, Inc.; and Samantak Ghosh, IP Counsel at Gilead Sciences.